Evidence map›Paper›PMID 23934211›Full record

ReviewPsychopharmacology2013

The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.

Maddalena Mereu, Antonello Bonci, Amy Hauck Newman, Gianluigi Tanda

Open access · greenAbstract readReview
In one paragraph

Review in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 146 citations in OpenAlex.

  1. Trial
  2. Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study With High-Resolution PET and [(11)C]-PE2I.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Modafinil, an atypical CNS stimulant?Advances in pharmacology (San Diego, Calif.) · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Maddalena MereuMolecular Targets and Medication Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, DHHS, 251 Bayview Boulevard, NIDA Suite 200, Baltimore, MD, USA.
Antonello Bonci
Amy Hauck Newman
Gianluigi Tanda
National Institute on Drug Abuse · USNational Institutes of Health · US

Funding

Novel Probes for the Monoamine TransportersZIADA000389 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$14.4M
Intramural NIH HHS Z99 DA999999
6 · The paper itself

Abstract

RATIONALE AND

objectivesModafinil (MOD) and its R-enantiomer (R-MOD) are approved medications for narcolepsy and other sleep disorders. They have also been used, off-label, as cognitive enhancers in populations of patients with mental disorders, including substance abusers that demonstrate impaired cognitive function. A debated nonmedical use of MOD in healthy individuals to improve intellectual performance is raising questions about its potential abuse liability in this population. RESULTS AND

conclusionsMOD has low micromolar affinity for the dopamine transporter (DAT). Inhibition of dopamine (DA) reuptake via the DAT explains the enhancement of DA levels in several brain areas, an effect shared with psychostimulants like cocaine, methylphenidate, and the amphetamines. However, its neurochemical effects and anatomical pattern of brain area activation differ from typical psychostimulants and are consistent with its beneficial effects on cognitive performance processes such as attention, learning, and memory. At variance with typical psychostimulants, MOD shows very low, if any, abuse liability, in spite of its use as a cognitive enhancer by otherwise healthy individuals. Finally, recent clinical studies have focused on the potential use of MOD as a medication for treatment of drug abuse, but have not shown consistent outcomes. However, positive trends in several result measures suggest that medications that improve cognitive function, like MOD or R-MOD, may be beneficial for the treatment of substance use disorders in certain patient populations.

Indexed as

Off-Label UseBenzhydryl CompoundsBrainCognitionDopamineDopamine Plasma Membrane Transport ProteinsHumansModafinilMolecular StructureNeurobiologyNootropic AgentsSubstance-Related DisordersSynaptic TransmissionBenzhydryl CompoundsDopamineDopamine Plasma Membrane Transport ProteinsModafinilNootropic Agents

Identifiers

PMID23934211
PMCPMC3800148
OpenAlexW2028455835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.